Compare · CRY vs MDLN
CRY vs MDLN
Side-by-side comparison of CryoLife Inc. (CRY) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRY and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 62.2x CRY ($753.2M).
- Over the past year, CRY is down 32.6% and MDLN is down 14.3% - MDLN leads by 18.3 points.
- MDLN has hit the wire 12 times in the past 4 weeks while CRY has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 4 for CRY).
- Company
- CryoLife Inc.
- Medline Inc.
- Price
- $17.30-0.75%
- $34.92-2.02%
- Market cap
- $753.2M
- $46.86B
- 1M return
- -4.58%
- -13.80%
- 1Y return
- -32.58%
- -14.31%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 12
- Recent ratings
- 4
- 25
CryoLife Inc.
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Latest CRY
- GraniteShares Expands YieldBOOST(TM) Lineup with Launch of CRY and XEY ETFs
- CryoLife Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- CryoLife Announces Corporate Rebranding And Changes Name To Artivion; Will Change Ticker To 'AORT' Effective Jan. 24
- CryoLife Announces Corporate Rebranding and Changes Name to Artivion
- Morgan Stanley Maintains Equal-Weight on Cryolife, Lowers Price Target to $25
- Morgan Stanley reiterated coverage on Cryolife with a new price target
- SEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)
- CryoLife, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 4: Horton Amy sold $46,422 worth of shares (2,500 units at $18.57) and gifted 1,500 shares, decreasing direct ownership by 4% to 85,282 units
- SEC Form 4: Davis John E bought $10,398 worth of shares (600 units at $17.33), increasing direct ownership by 0.83% to 72,499 units
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.